LivaNova’s OSPREY Trial Success Drives Buy Recommendation Amid Market Potential
Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...
Grand Rapids Herald-Review2h
Minnesota Has the 13th Lowest Rate of GLP-1 Use in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
CBS19 News12m
Virginia Residents Are Using GLP-1s at a Below Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
KTEN19h
Texas Has the 10th Lowest Rate of GLP-1 Use in the Nation
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...
The Manhattan Mercury2h
Kansas Residents Are Using GLP-1s at an Above Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
MassDevice21h
LivaNova nerve stim for sleep apnea meets primary study endpoints
LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...
TiogaPublishing.com19h
Pennsylvania Residents Are Using GLP-1s at the 10th Highest Rate in the Country
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...
Southwest Iowa News2h
Iowa Has the 9th Highest Rate of GLP-1 Use in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Hastings Tribune2h
Nebraska Residents Are Using GLP-1s at a Slightly Above Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Messenger-Inquirer2h
Kentucky Has the Highest Rate of GLP-1 Use in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Rome Sentinel19h
New York Has the 14th Highest Rate of GLP-1 Use in the Nation
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...
Grainger County3h
Tennessee Residents Are Using GLP-1s at the 13th Highest Rate in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...